Last reviewed · How we verify
Moderate to severe plaque psoriasis and Crohn's disease
Approved treatments
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe plaque psoriasis and Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe plaque psoriasis and Crohn's disease treatment landscape brief
- Moderate to severe plaque psoriasis and Crohn's disease treatment updates RSS
Frequently asked questions about Moderate to severe plaque psoriasis and Crohn's disease
What drugs treat Moderate to severe plaque psoriasis and Crohn's disease?
Tracked treatments include Chronic- PF-06480605 50 mg SC Q4W.
What is the treatment for Moderate to severe plaque psoriasis and Crohn's disease?
Standard treatment for Moderate to severe plaque psoriasis and Crohn's disease includes Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe plaque psoriasis and Crohn's disease patent cliff · Moderate to severe plaque psoriasis and Crohn's disease CI report
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing